Prof. Ignatius Ou Sai Hong, Dr. James Suh, Dr. Wong Seng Weng, Dr. Amit Verma, 20170514091000
As targeted cancer therapy options are increasing, it is becoming more important to choose the most appropriate treatment for patients with cancer. At a Roche-sponsored symposium held during the 2nd ESMO Asia Congress in Singapore, four experts discussed the potential of comprehensive genomic profiling (CGP) for personalizing cancer care and helping healthcare professionals to make the best treatment decisions for individual patients.
Dr. Ross Soo, Prof. James Chih-Hsin Yang, Prof. Tony Mok, Prof. Fred Hirsch, 20170328111500
Classification and treatment of non-small cell lung cancer (NSCLC) has greatly evolved in recent years. A better understanding of this complex malignancy has led to a shift from histologic diagnosis to more accurate subclassification using molecular screening which, in turn, led to the transition from empiric treatment to molecular target therapy. At the European Society for Medical Oncology (ESMO) Asia 2016 Congress in Singapore, Dr Ross Soo from the National University Cancer Institute, Singapore, Professor James Chih-Hsin Yang from the National Taiwan University Hospital, Taiwan, Professor Tony Mok from The Chinese University of Hong Kong, Hong Kong, and Professor Fred Hirsch from the University of Colorado Cancer Center, Colorado, US presented therapeutic biomarker-driven strategies for improving outcomes in patients with NSCLC. The discussion focused on the role and impact of molecular target therapy using epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) biomarkers and T-cell-based immunotherapy in coming up with algorithms to guide clinicians in selecting the best treatment regimen for each patient.
Over 20 leading surgical and medical oncologists from Singapore attended a dinner meeting on the Neoadjuvant treatment of early breast cancer (eBC). Co-chaired by Dr Veronique Tan (National Cancer Centre, Singapore) and Dr Elaine Lim (National Cancer Centre, Singapore), the meeting served as a platform to discuss the role of neoadjuvant therapy in eBC management. Guest speakers, Professor J. Michael Dixon OBE (Edinburgh Breast Unit, Western General Hospital, Edinburgh, United Kingdom) and Dr Rebecca Dent (National Cancer Centre, Singapore) shared their perspectives on the benefits of neoadjuvant therapy in different BC subtypes.
At the launch of Caris Molecular Intelligence® in Malaysia, Dr Andrew Dean, Head of Oncology at the St John of God Subianco Hospital, Perth, shared with the audience on molecular profiling and its benefits, with a focus on the Caris Molecular Intelligence® service.
The genomics of cancer patients affect their responses to therapies. Some genomic alterations in cancer genes are better treated with targeted therapies, and physicians informed by genomic profiles of their patients can better decide on optimal treatments. Next-generation sequencing (NGS) technology has facilitated rapid and inexpensive gene sequencing for clinical use. This article discusses NGS applications for cancer management, focusing on comprehensive genomic profiling (CGP).
Sorafenib appears to be well-tolerated in patients with hepatocellular carcinoma (HCC), with the subgroup of Child-Pugh B patients having a shorter treatment duration and higher serious adverse event (SAE) incidence, according to the results of a subgroup analysis of GIDEON*.
New-generation therapies targeted toward specific genetic alterations such as EGFR and ALK mutations in non-small cell lung cancer (NSCLC) can overcome resistance to first-generation therapies and improve survival of patients, according to a presentation at the 21st Congress of the Asian Pacific Society of Respirology (APSR 2016) held in Bangkok, Thailand.
A 55-year-old man presented with almost one year history of heat intolerance, mild palpitation and significant weight loss. Free T3 and T4 were elevated with normal TSH. Patient had suboptimal response to carbimazole therapy.
Data from the first whole genome sequencing in a large group of long-term childhood cancer survivors enrolled in the St. Jude Lifetime Cohort Study revealed that 12 percent of childhood cancer survivors have germline mutations in genes known to predispose them to cancers and subsequent neoplasms.
Women with higher age at breast cancer diagnosis and Indian women are at a higher risk of cardiovascular disease (CVD) mortality after diagnosis, a new prospective cohort study shows. However, risk of CVD mortality within 10 years after diagnosis remains low in Southeast Asia.